Efficacy and safety of antiangiogenic therapy (bevacizumab or apatinib) plus chemotherapy in patients with platinum‑resistant recurrent ovarian cancer: A retrospective study

Li,Huifen; Xiao,Jianjun; Tian,Muyou

doi:10.3892/ol.2024.14790

Efficacy and safety of antiangiogenic therapy (bevacizumab or apatinib) plus chemotherapy in patients with platinum‑resistant recurrent ovarian cancer: A retrospective study

Authors:
- Huifen Li
- Jianjun Xiao
- Muyou Tian
View Affiliations

Affiliations: Department of Medical Oncology, People's Hospital of Zhongshan City, Zhongshan, Guangdong 528403, P.R. China
Published online on: November 5, 2024 https://doi.org/10.3892/ol.2024.14790
Article Number: 44
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The majority of patients with ovarian cancer will relapse and subsequently develop platinum‑resistant recurrent ovarian cancer (PRROC). Antiangiogenic therapy plus chemotherapy may be a potential treatment option in patients with PRROC. However, further evidence is required to facilitate clinical application. The present study aimed to investigate the efficacy and safety of antiangiogenic therapy (bevacizumab or apatinib) plus chemotherapy in patients with PRROC. Data from 86 patients with PRROC receiving antiangiogenic therapy (bevacizumab or apatinib) plus chemotherapy (pegylated liposomal doxorubicin, weekly‑paclitaxel or gemcitabine) were reviewed retrospectively. Data for treatment response, progression‑free survival (PFS), overall survival (OS) and adverse events were obtained. Complete response, partial response, stable disease and progressive disease rates were 0.0, 33.7, 44.2 and 22.1%, respectively. Objective response and disease control rates were 33.7 and 77.9%, respectively. Median (and 95% confidence intervals) PFS and OS values were 6.5 (4.7‑8.2) and 20.3 (14.1‑26.5) months, respectively. PFS (P=0.016) and OS (P=0.005) durations were longer in patients that received the antiangiogenic plus chemotherapy regimen as a second‑line treatment vs. patients that received it as a third‑line or above treatment. Ascites (yes vs. no) and current treatment lines (third or above vs. second) were independently associated with shorter PFS and OS (all P<0.05). The most frequent treatment‑induced adverse events were leukopenia (34.9%), hypertension (30.2%) and fatigue (30.2%). All adverse events were considered acceptable and only previously reported adverse events were observed. The findings of the present study may provide further clinical evidence for the application of antiangiogenic therapy plus chemotherapy in patients with PRROC.

View Figures

View References

1	Momenimovahed Z, Tiznobaik A, Taheri S and Salehiniya H: Ovarian cancer in the world: Epidemiology and risk factors. Int J Womens Health. 11:287–299. 2019. View Article : Google Scholar : PubMed/NCBI
2	Mazidimoradi A, Momenimovahed Z, Allahqoli L, Tiznobaik A, Hajinasab N, Salehiniya H and Alkatout I: The global, regional and national epidemiology, incidence, mortality, and burden of ovarian cancer. Health Sci Rep. 5:e9362022. View Article : Google Scholar : PubMed/NCBI
3	Ali AT, Al-Ani O and Al-Ani F: Epidemiology and risk factors for ovarian cancer. Prz Menopauzalny. 22:93–104. 2023.PubMed/NCBI
4	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
5	Zamwar UM and Anjankar AP: Aetiology, epidemiology, histopathology, classification, detailed evaluation, and treatment of ovarian cancer. Cureus. 14:e305612022.PubMed/NCBI
6	Chandra A, Pius C, Nabeel M, Vishwanatha JK, Ahmad S and Basha R: Ovarian cancer: Current status and strategies for improving therapeutic outcomes. Cancer Med. 8:7018–7031. 2019. View Article : Google Scholar : PubMed/NCBI
7	Luvero D, Milani A and Ledermann JA: Treatment options in recurrent ovarian cancer: Latest evidence and clinical potential. Ther Adv Med Oncol. 6:229–239. 2014. View Article : Google Scholar : PubMed/NCBI
8	Singh N, Jayraj AS, Sarkar A, Mohan T, Shukla A and Ghatage P: Pharmacotherapeutic treatment options for recurrent epithelial ovarian cancer. Expert Opin Pharmacother. 24:49–64. 2023. View Article : Google Scholar : PubMed/NCBI
9	Havasi A, Cainap SS, Havasi AT and Cainap C: Ovarian Cancer-Insights into platinum resistance and overcoming it. Medicina (Kaunas). 59:5442023. View Article : Google Scholar : PubMed/NCBI
10	Richardson DL, Eskander RN and O'Malley DM: Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: A narrative review. JAMA Oncol. 9:851–859. 2023. View Article : Google Scholar : PubMed/NCBI
11	Elyashiv O, Aleohin N, Migdan Z, Leytes S, Peled O, Tal O and Levy T: The poor prognosis of acquired secondary platinum resistance in ovarian cancer patients. Cancers (Basel). 16:6412024. View Article : Google Scholar : PubMed/NCBI
12	Liu ZL, Chen HH, Zheng LL, Sun LP and Shi L: Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 8:1982023. View Article : Google Scholar : PubMed/NCBI
13	Mei C, Gong W, Wang X, Lv Y, Zhang Y, Wu S and Zhu C: Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine. Front Pharmacol. 14:11477172023. View Article : Google Scholar : PubMed/NCBI
14	Wang T, Tang J, Yang H, Yin R, Zhang J, Zhou Q, Liu Z, Cao L, Li L, Huang Y, et al: Effect of apatinib plus pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone on platinum-resistant recurrent ovarian cancer: The APPROVE randomized clinical trial. JAMA Oncol. 8:1169–1176. 2022. View Article : Google Scholar : PubMed/NCBI
15	Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, et al: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA Open-label randomized phase III trial. J Clin Oncol. 32:1302–1308. 2014. View Article : Google Scholar : PubMed/NCBI
16	Geng A, Yang H, Wang Z and Wu C: Apatinib plus paclitaxel versus paclitaxel monotherapy for platinum-resistant recurrent ovarian cancer treatment: A retrospective cohort study. J Clin Pharm Ther. 47:2264–2273. 2022. View Article : Google Scholar : PubMed/NCBI
17	Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Berek JS, Chen LM, Cristea M, DeRosa M, et al: NCCN guidelines insights: Ovarian cancer, version 1.2019. J Natl Compr Canc Netw. 17:896–909. 2019. View Article : Google Scholar : PubMed/NCBI
18	Schwartz LH, Litiere S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, et al: RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer. 62:132–137. 2016. View Article : Google Scholar : PubMed/NCBI
19	Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Cristea M, DeRosa M, Eisenhauer EL, et al: Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 19:191–226. 2021. View Article : Google Scholar : PubMed/NCBI
20	Berek JS, Renz M, Kehoe S, Kumar L and Friedlander M: Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet. 155 (Suppl 1):S61–S85. 2021. View Article : Google Scholar
21	Vergote I, Gonzalez-Martin A, Lorusso D, Gourley C, Mirza MR, Kurtz JE, Okamoto A, Moore K, Kridelka F, McNeish I, et al: Clinical research in ovarian cancer: Consensus recommendations from the Gynecologic Cancer InterGroup. Lancet Oncol. 23:e374–e384. 2022. View Article : Google Scholar : PubMed/NCBI
22	Le T, Hopkins L, Baines KA, Rambout L, Al Hayki M and Kee Fung MF: Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer. Gynecol Oncol. 102:49–53. 2006. View Article : Google Scholar : PubMed/NCBI
23	Fukumura D, Kloepper J, Amoozgar Z, Duda DG and Jain RK: Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges. Nat Rev Clin Oncol. 15:325–340. 2018. View Article : Google Scholar : PubMed/NCBI
24	Qiu H, Li J, Liu Q, Tang M and Wang Y: Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel. Cell Cycle. 17:1235–1244. 2018. View Article : Google Scholar : PubMed/NCBI
25	Volk LD, Flister MJ, Chihade D, Desai N, Trieu V and Ran S: Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases. Neoplasia. 13:327–338. 2011. View Article : Google Scholar : PubMed/NCBI
26	Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Gehrs B, Raffeld M, Kinders RJ, Parchment R, et al: Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther. 8:1867–1877. 2009. View Article : Google Scholar : PubMed/NCBI
27	Cesca M, Morosi L, Berndt A, Fuso Nerini I, Frapolli R, Richter P, Decio A, Dirsch O, Micotti E, Giordano S, et al: Bevacizumab-Induced inhibition of angiogenesis promotes a more homogeneous intratumoral distribution of paclitaxel, improving the antitumor response. Mol Cancer Ther. 15:125–135. 2016. View Article : Google Scholar : PubMed/NCBI
28	Yang H, Geng A, Wang Z and Wu C: Efficacy and safety of apatinib combined with liposomal doxorubicin or paclitaxel versus liposomal doxorubicin or paclitaxel monotherapy in patients with recurrent platinum-resistant ovarian cancer. J Obstet Gynaecol Res. 49:1611–1619. 2023. View Article : Google Scholar : PubMed/NCBI
29	Fukuda T, Noda T, Uchikura E, Awazu Y, Tasaka R, Imai K, Yamauchi M, Ichimura T, Yasui T and Sumi T: Real-world efficacy and safety of bevacizumab for advanced or recurrent mullerian cancer: A Single-institutional experience. Anticancer Res. 43:3097–3105. 2023. View Article : Google Scholar : PubMed/NCBI
30	Ford CE, Werner B, Hacker NF and Warton K: The untapped potential of ascites in ovarian cancer research and treatment. Br J Cancer. 123:9–16. 2020. View Article : Google Scholar : PubMed/NCBI
31	Simion L, Rotaru V, Cirimbei C, Stefan DC, Gherghe M, Ionescu S, Tanase BC, Luca DC, Gales LN and Chitoran E: Analysis of efficacy-to-safety ratio of angiogenesis-inhibitors based therapies in ovarian cancer: A systematic review and Meta-analysis. Diagnostics (Basel). 13:10402023. View Article : Google Scholar : PubMed/NCBI
32	Wang Y, Lin H, Ou Y, Fu H, Tsai C, Chien CC and Wu C: Safety analysis of bevacizumab in ovarian cancer patients. J Clin Med. 12:20652023. View Article : Google Scholar : PubMed/NCBI
33	Verschraegen CF, Czok S, Muller CY, Boyd L, Lee SJ, Rutledge T, Blank S, Pothuri B, Eberhardt S and Muggia F: Phase II study of bevacizumab with liposomal doxorubicin for patients with Platinum- and taxane-resistant ovarian cancer. Ann Oncol. 23:3104–3110. 2012. View Article : Google Scholar : PubMed/NCBI